NEWS

Thieme Launches New Open Access Journal Therapeutics NOW

Thieme is expanding its open access portfolio to promote evidence-based therapeutic development. Therapeutics NOW will publish significant work in fields such as gene therapy, immunotherapy, drug discovery, targeted delivery systems, and personalized medicine. The journal connects experts from academia, industry, and clinical practice worldwide, aiming to rapidly incorporate evidence-based research findings into patient care. Authors benefit from fast, professional and efficient peer review processes to publish and disseminate their research open access.

Interdisciplinary by Design

Therapeutics NOW brings together researchers from chemistry, biology, engineering, clinical science, and policy. This interdisciplinary scope reflects the complexity of modern healthcare and supports a systems-level understanding of therapeutic innovation. Each published article features a Research Significance Highlight, which enables readers to quickly assess its translational relevance.

“The global need for safe, effective, and accessible therapeutics has never been more urgent. Therapeutics NOW was established to support the rapid, evidence-based dissemination of information that strengthens the connection between fundamental discovery and real-world application,” emphasizes Prof. Natalia Tretyakova of the University of Minnesota–Twin Cities, Editor in Chief of Therapeutics NOW.

Fast, Rigorous, and Transparent Review

To uphold scientific integrity while enabling rapid communication, the journal uses Select Crowd Review (SCR). This innovative approach allows for a fast and effective review process, with the aim to provide a first decision after peer review in less than a week from submission. Feedback from experts in various research areas ensures high-quality reviews and visibility in the academic community.

“With Therapeutics NOW, we are redefining how quickly essential research can reach the people who need it most. Our open-access, fast-track, rigorous, and collaborative crowd peer review ensures that breakthroughs in infectious disease and therapeutic science are shared rapidly and transparently, driving faster progress toward new treatments and cures,” says Dr Kathleen Too, Senior Vice President Chemistry at Thieme.

Broad Scope and Article Formats Tailored for Impact

The journal welcomes contributions from the therapeutic sciences, including applied computational biology, drug discovery and development, biopharmaceuticals, theragnostics, synthetic biology, cancer biology, and immunotherapy, preventive medicine, diagnostics, and biomedical engineering. Article types range from original and review articles to industrial case studies and policy and impact briefs - providing formats suited to regulatory, translational, and real-world insights. Each article will contain a significance / impact box explaining the importance of the work to researchers outside the specific field. It aims at maximizing the understanding of the work to a multidisciplinary audience.

Global Accessibility through Gold Open Access

All content in Therapeutics NOW is freely accessible worldwide, enabling broad dissemination and engagement across the academic, industrial, and healthcare sectors. The journal aims to catalyze breakthroughs that meaningfully improve patient outcomes by connecting diverse scientific communities and highlighting translational significance.

Authors interested in publishing articles in Therapeutics NOW
can find all the necessary information at:
https://lp.thieme.de/journals/therapeutics-now/2944-0548